In the process of drug development, the evaluation of the efficacy of drug candidates on the animal model is an essential link. The effect of a new drug candidate is finally confirmed in the animal pharmacology and disease models, only then can the biologically active compound be transformed into the drug candidate and enter the development stage. However, experimental animals with similar genetic backgrounds can exhibit different effects or toxic reactions after receiving the same chemical or dietary interventions. This makes it difficult to collect or reproduce data from animal experiments, to a certain extent, increase the difficulty of drug candidate evaluation, and even cover up the actual efficacy or toxicity of the drug candidate, bringing risks to clinical application.
Figure 1. The typical pulse sequences utilized in NMR-based pharmacometabonomics and the respective spectra of plasma sample. (Zhang L.; et al. 2016)
Pharmacometabonomics, as a systematic approach, can play a huge role in these aspects. The study of metabolomics can distinguish the metabolic states of different animal models, look for the metabolic differences in human disease states, and find animal models more suitable for studying human diseases. Creative Biostructure offers NMR-based pharmacometabonomics solutions to help you select appropriate animal models, evaluate drug metabolism, better understand the pharmacokinetic properties, and assess drug safety through the quantification and analysis of metabolites.
Supported by dozens of scientists with extensive experience in NMR spectroscopy, Creative Biostructure provides global customers with drug discovery and preclinical research needs with NMR-based pharmacometabonomics service, which is an unbiased and efficient approach for rapid metabolism, and selection of animal models, as well as evaluation of lead drug candidates.